| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 27 | 2017 | 2390 | 2.720 |
Why?
|
| Purine Nucleosides | 5 | 2013 | 48 | 1.560 |
Why?
|
| Pyrimidinones | 5 | 2013 | 314 | 1.540 |
Why?
|
| Apoptosis | 21 | 2017 | 7591 | 1.140 |
Why?
|
| Gossypol | 3 | 2012 | 28 | 1.080 |
Why?
|
| Purine-Nucleoside Phosphorylase | 4 | 2010 | 46 | 1.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 10 | 2017 | 1493 | 0.960 |
Why?
|
| Gene Expression Regulation, Leukemic | 4 | 2017 | 560 | 0.920 |
Why?
|
| Bone Marrow Cells | 4 | 2016 | 943 | 0.840 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 6 | 2017 | 275 | 0.770 |
Why?
|
| Stromal Cells | 6 | 2017 | 825 | 0.640 |
Why?
|
| Lymphocytes | 7 | 2016 | 1234 | 0.560 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2012 | 367 | 0.490 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 369 | 0.470 |
Why?
|
| Boronic Acids | 4 | 2018 | 362 | 0.440 |
Why?
|
| Pyrazines | 2 | 2016 | 495 | 0.440 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2012 | 72 | 0.430 |
Why?
|
| Chemokine CXCL2 | 1 | 2012 | 35 | 0.430 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 1265 | 0.430 |
Why?
|
| Hydrogen Peroxide | 4 | 2018 | 217 | 0.420 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 204 | 0.420 |
Why?
|
| Antineoplastic Agents | 14 | 2017 | 14289 | 0.400 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 203 | 0.400 |
Why?
|
| Adenosine Triphosphate | 5 | 2017 | 571 | 0.400 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 1879 | 0.380 |
Why?
|
| Caspases | 4 | 2016 | 661 | 0.350 |
Why?
|
| Protein Kinases | 2 | 2021 | 874 | 0.340 |
Why?
|
| Vidarabine | 3 | 2017 | 1341 | 0.340 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2008 | 37 | 0.330 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 482 | 0.330 |
Why?
|
| Autophagy | 1 | 2013 | 927 | 0.300 |
Why?
|
| Nitrogen Mustard Compounds | 2 | 2018 | 73 | 0.280 |
Why?
|
| Cell Survival | 8 | 2017 | 3045 | 0.280 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2021 | 713 | 0.280 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2016 | 4757 | 0.270 |
Why?
|
| Hydrazones | 2 | 2016 | 42 | 0.260 |
Why?
|
| Intercalating Agents | 2 | 2017 | 29 | 0.260 |
Why?
|
| Piperazines | 5 | 2016 | 2101 | 0.250 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 852 | 0.240 |
Why?
|
| Multiple Myeloma | 2 | 2013 | 2138 | 0.230 |
Why?
|
| Coculture Techniques | 5 | 2019 | 626 | 0.230 |
Why?
|
| Adenosine | 1 | 2005 | 289 | 0.230 |
Why?
|
| Drug Design | 2 | 2018 | 375 | 0.220 |
Why?
|
| B-Lymphocytes | 5 | 2019 | 1294 | 0.220 |
Why?
|
| RNA, Messenger | 7 | 2016 | 6150 | 0.220 |
Why?
|
| Receptors, Antigen, B-Cell | 2 | 2017 | 171 | 0.220 |
Why?
|
| Bendamustine Hydrochloride | 3 | 2017 | 107 | 0.210 |
Why?
|
| Bone Marrow | 1 | 2010 | 2358 | 0.210 |
Why?
|
| Pyrroles | 1 | 2006 | 576 | 0.210 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 588 | 0.210 |
Why?
|
| Pyrimidines | 4 | 2016 | 3518 | 0.210 |
Why?
|
| Pyrazoles | 3 | 2016 | 1471 | 0.200 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 2 | 2016 | 119 | 0.200 |
Why?
|
| Prodrugs | 2 | 2014 | 217 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 6 | 2017 | 5395 | 0.200 |
Why?
|
| Deoxyguanine Nucleotides | 2 | 2013 | 21 | 0.200 |
Why?
|
| Transcription, Genetic | 4 | 2019 | 3154 | 0.200 |
Why?
|
| Humans | 41 | 2021 | 261506 | 0.190 |
Why?
|
| Ataxia Telangiectasia | 1 | 2021 | 62 | 0.190 |
Why?
|
| Receptors, CXCR5 | 1 | 2019 | 27 | 0.170 |
Why?
|
| Oxidative Phosphorylation | 2 | 2017 | 253 | 0.170 |
Why?
|
| T-Lymphocytes | 3 | 2016 | 3869 | 0.170 |
Why?
|
| Nitrophenols | 2 | 2016 | 92 | 0.170 |
Why?
|
| Cell Communication | 3 | 2017 | 509 | 0.170 |
Why?
|
| Cells, Cultured | 7 | 2017 | 5637 | 0.170 |
Why?
|
| Energy Metabolism | 1 | 2005 | 992 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 430 | 0.170 |
Why?
|
| DNA | 3 | 2017 | 2693 | 0.160 |
Why?
|
| Reactive Oxygen Species | 3 | 2014 | 987 | 0.160 |
Why?
|
| Purines | 2 | 2017 | 273 | 0.160 |
Why?
|
| Zinc | 2 | 2016 | 188 | 0.160 |
Why?
|
| Biphenyl Compounds | 2 | 2016 | 194 | 0.160 |
Why?
|
| Glycolysis | 2 | 2017 | 519 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2011 | 2947 | 0.150 |
Why?
|
| Indolequinones | 1 | 2017 | 4 | 0.150 |
Why?
|
| Benzene Derivatives | 1 | 2017 | 23 | 0.150 |
Why?
|
| Animals | 14 | 2021 | 59536 | 0.150 |
Why?
|
| Quinazolinones | 1 | 2017 | 51 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 3639 | 0.140 |
Why?
|
| Sulfonamides | 2 | 2016 | 1823 | 0.140 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 582 | 0.140 |
Why?
|
| Mitochondria | 2 | 2017 | 1282 | 0.140 |
Why?
|
| DNA Damage | 3 | 2017 | 1954 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 4938 | 0.130 |
Why?
|
| Chelating Agents | 1 | 2016 | 127 | 0.130 |
Why?
|
| Fibroblasts | 3 | 2017 | 1682 | 0.130 |
Why?
|
| Caspases, Effector | 1 | 2014 | 5 | 0.130 |
Why?
|
| Mice | 10 | 2021 | 34495 | 0.130 |
Why?
|
| Cell Proliferation | 5 | 2017 | 7226 | 0.130 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 591 | 0.130 |
Why?
|
| Protein Domains | 1 | 2016 | 314 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 1217 | 0.120 |
Why?
|
| Cross-Linking Reagents | 1 | 2014 | 153 | 0.120 |
Why?
|
| Deoxycytidine Kinase | 1 | 2013 | 27 | 0.120 |
Why?
|
| Ribonucleotide Reductases | 1 | 2013 | 51 | 0.120 |
Why?
|
| Flow Cytometry | 3 | 2016 | 3033 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2016 | 621 | 0.110 |
Why?
|
| Cell Line, Tumor | 10 | 2018 | 14551 | 0.110 |
Why?
|
| Mice, Knockout | 3 | 2019 | 5710 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2016 | 1546 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2016 | 1756 | 0.110 |
Why?
|
| Mechlorethamine | 1 | 2011 | 51 | 0.100 |
Why?
|
| Leukemic Infiltration | 1 | 2011 | 72 | 0.100 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 276 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1586 | 0.100 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2011 | 157 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 15862 | 0.100 |
Why?
|
| Benzamides | 1 | 2016 | 1832 | 0.100 |
Why?
|
| Blotting, Western | 3 | 2016 | 3536 | 0.100 |
Why?
|
| Neoplasm Proteins | 3 | 2009 | 3230 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 419 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2010 | 45 | 0.090 |
Why?
|
| Acute Disease | 2 | 2013 | 2422 | 0.090 |
Why?
|
| Immunoblotting | 2 | 2017 | 886 | 0.090 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 1688 | 0.090 |
Why?
|
| 2-Chloroadenosine | 1 | 2009 | 37 | 0.090 |
Why?
|
| Bortezomib | 1 | 2011 | 543 | 0.090 |
Why?
|
| Oxazines | 1 | 2009 | 43 | 0.090 |
Why?
|
| Male | 12 | 2019 | 123000 | 0.080 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2010 | 243 | 0.080 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2015 | 923 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2016 | 895 | 0.080 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2008 | 25 | 0.080 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2008 | 19 | 0.080 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 486 | 0.080 |
Why?
|
| Embryo, Mammalian | 3 | 2017 | 741 | 0.080 |
Why?
|
| Aged | 10 | 2017 | 70117 | 0.080 |
Why?
|
| Mitochondrial Membranes | 1 | 2008 | 58 | 0.080 |
Why?
|
| Biological Transport, Active | 1 | 2008 | 131 | 0.080 |
Why?
|
| Caspase Inhibitors | 1 | 2008 | 95 | 0.080 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2008 | 94 | 0.080 |
Why?
|
| Molecular Mimicry | 1 | 2008 | 72 | 0.080 |
Why?
|
| Calpain | 1 | 2008 | 64 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 3472 | 0.080 |
Why?
|
| Deoxyguanosine | 1 | 2007 | 37 | 0.080 |
Why?
|
| Signal Transduction | 5 | 2016 | 11965 | 0.080 |
Why?
|
| Dipeptides | 1 | 2008 | 91 | 0.080 |
Why?
|
| Superoxides | 1 | 2008 | 211 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5178 | 0.080 |
Why?
|
| Female | 12 | 2019 | 141928 | 0.080 |
Why?
|
| Biosynthetic Pathways | 1 | 2007 | 46 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2021 | 4804 | 0.080 |
Why?
|
| Leukemia, T-Cell | 1 | 2007 | 87 | 0.080 |
Why?
|
| DNA Repair | 2 | 2013 | 1872 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2008 | 143 | 0.080 |
Why?
|
| Adenine | 3 | 2016 | 631 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2013 | 2796 | 0.070 |
Why?
|
| Esters | 2 | 2018 | 45 | 0.070 |
Why?
|
| Adult | 8 | 2021 | 77950 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 4844 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 2864 | 0.070 |
Why?
|
| Middle Aged | 9 | 2017 | 86204 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2010 | 1544 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 1618 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2017 | 336 | 0.070 |
Why?
|
| Antioxidants | 1 | 2008 | 507 | 0.060 |
Why?
|
| Piperidines | 3 | 2016 | 1035 | 0.060 |
Why?
|
| Prognosis | 3 | 2017 | 21713 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 2315 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 548 | 0.060 |
Why?
|
| Gene Expression | 1 | 2012 | 3570 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 709 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2008 | 2074 | 0.060 |
Why?
|
| Pyridines | 1 | 2009 | 1244 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2014 | 566 | 0.050 |
Why?
|
| Cell Death | 2 | 2014 | 671 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 14889 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 4320 | 0.040 |
Why?
|
| Palatine Tonsil | 1 | 2019 | 53 | 0.040 |
Why?
|
| Adenine Nucleotides | 2 | 2013 | 351 | 0.040 |
Why?
|
| Germinal Center | 1 | 2019 | 161 | 0.040 |
Why?
|
| Arabinonucleosides | 2 | 2013 | 437 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 4143 | 0.040 |
Why?
|
| Young Adult | 2 | 2013 | 21445 | 0.040 |
Why?
|
| Infant | 1 | 2013 | 13310 | 0.040 |
Why?
|
| Ribonucleotides | 1 | 2017 | 52 | 0.040 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 102 | 0.040 |
Why?
|
| Intracellular Space | 1 | 2017 | 77 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2021 | 1643 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 3719 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8873 | 0.040 |
Why?
|
| Proteins | 1 | 2005 | 1963 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2013 | 16273 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 446 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 401 | 0.030 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2016 | 170 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 471 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2013 | 2084 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 854 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 521 | 0.030 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 25 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 29902 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2015 | 196 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2015 | 116 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2014 | 311 | 0.030 |
Why?
|
| Thiourea | 1 | 2013 | 18 | 0.030 |
Why?
|
| Lymphoma, Follicular | 1 | 2019 | 587 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 478 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 3552 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 2013 | 3001 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1313 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2014 | 240 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 1062 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1130 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2016 | 1258 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 1146 | 0.030 |
Why?
|
| Adolescent | 1 | 2013 | 31252 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2013 | 274 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 931 | 0.030 |
Why?
|
| Child | 1 | 2013 | 29154 | 0.030 |
Why?
|
| Rituximab | 1 | 2017 | 1528 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 703 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2011 | 385 | 0.030 |
Why?
|
| Time Factors | 1 | 2005 | 12926 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 1764 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 13658 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1290 | 0.020 |
Why?
|
| Base Sequence | 1 | 2017 | 4917 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 607 | 0.020 |
Why?
|
| Syk Kinase | 1 | 2009 | 56 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2009 | 63 | 0.020 |
Why?
|
| Chemokine CCL3 | 1 | 2009 | 63 | 0.020 |
Why?
|
| Cell Line | 1 | 2017 | 5114 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2009 | 114 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 10035 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 138 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2019 | 4078 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 503 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2011 | 1869 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 577 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 4758 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 803 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 1910 | 0.010 |
Why?
|
| Survival Rate | 1 | 2017 | 12221 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 3821 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 6682 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 941 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 5159 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 6942 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 2522 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2010 | 2330 | 0.010 |
Why?
|
| Histones | 1 | 2007 | 1466 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2013 | 32848 | 0.010 |
Why?
|
| Neoplasms | 2 | 2017 | 15193 | 0.010 |
Why?
|